Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005659700
Tue, 29.07.2025
Eckert & Ziegler SE
Berlin, Germany, 29 July 2025. Eckert & Ziegler (ISIN DE0005659700) has entered a Master Service Agreement with Archeus Technologies (Archeus), a company developing multiple differentiated radiopharmaceutical therapies, for contract manufacturing of its novel investigational compound ART-101. The agreement supports Archeus’ upcoming Phase 1 cli [ … ]
Mon, 28.07.2025
Eckert & Ziegler SE
Berlin, July 28, 2025. The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) resolved on June 18, 2025, to increase the share capital using company funds by € 42,343,864 to € 63,515,796. The capital increase was entered in the commercial register on 25 July 2025 and thus became effective. As a result, the company's share capital [ … ]
Tue, 15.07.2025
Eckert & Ziegler SE
Berlin, July 15, 2025. Eckert & Ziegler SE (ISIN DE0005659700) has been recognized by the Berlin Chamber of Industry and Commerce (IHK) for the exceptional quality of its training program for the fourth time in a row. The Berlin-based healthcare company already held the award for “Excellent Training Quality” from 2019 to 2020, from 2021 to 2023 [ … ]
Wed, 18.06.2025
Eckert & Ziegler SE
Berlin, June 18, 2025. The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today approved the proposal of the Executive Board and Supervisory Board and resolved to pay a dividend of EUR 0.50 per share for the 2024 fiscal year.
As in the previous year, the Annual General Meeting was held as an in-person event at Eckert & Z [ … ]
Thu, 05.06.2025
Eckert & Ziegler SE
Berlin, Germany, 05 June 2025. Eckert & Ziegler (ISIN DE0005659700, TecDAX) congratulates Telix Pharmaceuticals Limited (Telix) on the approval of its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection) in Germany, where Eckert & Ziegler Radiopharma GmbH is the official distributor.
With [ … ]
Fri, 30.05.2025
Eckert & Ziegler SE
BOSTON, Mass., 30 May 2025. Eckert & Ziegler successfully completes the 3rd annual Boston Radionuclide Theranostics Forum, underscoring its continued leadership in the radiopharmaceutical industry. Building upon the success of the previous editions, this year's event gathered around 100 decision makers, renowned experts, key partners, and influ [ … ]
Fri, 23.05.2025
Eckert & Ziegler SE
Berlin, May 23, 2025. Eckert & Ziegler SE (ISIN DE0005659700) has once again been honored with the “Best Managed Companies Award”. The award, presented by Deloitte Private, UBS, the Frankfurter Allgemeine Zeitung and the Federation of German Industries (BDI), recognize excellently managed medium-sized companies throughout Germany. Eckert & [ … ]
Tue, 13.05.2025
Eckert & Ziegler SE
1st Quarter 2025:
Sales of € 68.2 million (previous year: € 67.6 million)
EBIT before special items of € 16.2 million (previous year: € 15.0 million)
Net income of 9.7 Mio. € (previous year: € 8.5 million)
Forecast 2025:
Sales of around € 320 million (confirmed)
EBIT before special items of around € 78 million (confirmed)
Berlin, 13 May 2025 [ … ]
Thu, 24.04.2025
Eckert & Ziegler SE
Berlin, 24 April 2025. Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler SE, today announced the signing of a manufacturing agreement with Pentixapharm, a clinical-stage biopharmaceutical company. Under the terms of the agreement, EZR will produce and distribute patient-specific doses of Y90-PentixaTher, Pentixa [ … ]
Fri, 11.04.2025
Eckert & Ziegler SE
Berlin, 11 April 2025. The Supervisory Board of Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) approved the Executive Board's resolution to propose a dividend of € 0.50 per share entitled to a dividend for the 2024 financial year at the Annual General Meeting to be held on June 18, 2025 in Berlin. The 2024 annual financial statements of Eckert [ … ]
